Patient Reported Outcomes With Fingolimod in Local Experience (PROFILE)
Phase of Trial: Phase IV
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PROFILE
- Sponsors Novartis
- 12 Oct 2017 Interim results of 3 month comparing satisfaction with previous treatment and fingolimod at three months, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 24 May 2017 Status changed from recruiting to completed.
- 21 Oct 2015 Planned End Date changed from 1 Jan 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.